This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
National Institute for Health and Care Excellence. Final appraisal determination. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. National Institute for Health and Care Excellence. 2015. Available at: https://www.nice.org.uk/guidance/TA375/documents/rheumatoid-arthritis-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-abatacept-and-tocilizumab-review-id537-final-appraisal-determination-document2. Accessed 19 Apr 2017.
Sullivan W, Hirst M, Beard S, Gladwell D, Fagnani F, López Bastida J, et al. Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. Eur J Health Econ. 2016;17:755–70.
Chilcott J, McCabe C, Tappenden P, O’Hagan A, Cooper NJ, Abrams K, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326:522 (discussion 522).
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20:S5–26.
Arnold RJG, Ekins S. Time for cooperation in health economics among the modelling community. PharmacoEconomics. 2010;28:609–13.
Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, et al. The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia. 2011;31:1116–30.
Afzali HHA, Karnon J. Addressing the challenge for well informed and consistent reimbursement decisions. PharmacoEconomics. 2011;29:823–5.
Lee D, Porter J, Hertel N, Hatswell AJ, Briggs A. Modelling comparative efficacy of drugs with different survival profiles: ipilimumab, vemurafenib and dacarbazine in advanced melanoma. BioDrugs. 2016;30:307–19.
National Institute for Health and Care Excellence. Final evaluation determination: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. 2016. Available at: https://www.nice.org.uk/guidance/HST3/documents/final-evaluation-determination-document. Accessed 19 Apr 2017.
Anthony J. Hatswell is an employee of BresMed Health Solutions, and Fleur Chandler is an employee of GlaxoSmithKline.
No funding was received for this manuscript
Conflicts of interest
Anthony J. Hatswell and Fleur Chandler declare no conflicts of interest.
About this article
Cite this article
Hatswell, A.J., Chandler, F. Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling. PharmacoEconomics 35, 755–757 (2017). https://doi.org/10.1007/s40273-017-0516-2
- Chronic Obstructive Pulmonary Disease
- Multiple Myeloma
- Muscular Dystrophy